Top Pharma Companies Analysed in Topical GlobalData Report Published at MarketPublishers.com05 Nov 2014 • by Natalie Aster
LONDON – The patent cliff is expected to erase around USD 65 billion in sales up to 2019 as some of the best-selling drugs face the loss of patent exclusivity. The drug manufacturers that are set to be badly beaten will include Otsuka, GSK, Eli Lilly, and AstraZeneca. Otsuka's atypical antipsychotic ABILIFY (aripiprazole) that it co-markets with Bristol-Myers Squibb is poised to lose USD 6.2 billion by end-2019 due to fierce generic competition. Likewise, GlaxoSmithKline’s Advair will see its sales skyrocket by USD 4.8 billion during the same period.
The combined peer group revenue and average operating profit margin remained unchanged as of 2013 in comparison with 2012. Revenue from the peer group came in slightly down by -0.2% to USD 718.7 billion. The average operating margin of the peer group was stable at 21.5%; this was, however, lower by 90 basis points from the year 2011. On the clinical front, R&D expenditure grew by USD 800 million to USD 111.9 billion in 2013, a hike of 0.7%.
Comprehensive report “PharmaLeaders: Global Pharmaceutical Market Benchmark Report - Retrospective and Forward-Looking Analysis of the Leading Pharmaceutical Companies” elaborated by GlobalData canvasses the world’s pharmaceutical marketplace, along with a detail analysis of each drug maker’s future competitive position plus detailed forecasts for the top 30 companies discussed. These firms are analysed on 25 financial metrics based on financial performance, cost containment, capital structure, among others, to showcase the various strategies being used by these companies to boost value for their shareholders and gain a competitive edge.
Additionally, the study provides a granular analysis of the major drivers and trends shaping the global pharma universe, including FDA approvals, R&D expenditure, generic and/or patent erosion, corporate strategies, asset value creation, partnering and acquisition activity, etc. Coverage of 11 therapeutic franchises is included. The study provides analysis of the market size, rates of growth, company share data, sales drivers of the top-selling drugs, pipeline development, sales forecast figures and product NPVs. The research publication also identifies the growth and revenue leaders across the USA, the EU, Asia (Japan), and the emerging nations.
PharmaLeaders: Global Pharmaceutical Market Benchmark Report - Retrospective and Forward-Looking Analysis of the Leading Pharmaceutical Companies
Published: October, 2014
Price: US$ 3,995.00
More comprehensive studies by the publisher can be found at GlobalData page.